Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug90 | ACEI/ARB Wiki | 0.71 |
| drug89 | ACEI Wiki | 0.71 |
| drug2595 | Non-ACEI/ARB Wiki | 0.71 |
Navigate: Correlations HPO
There are 2 clinical trials
Some authors have proposed the use of the flu vaccine to reduce the severity of COVID-19 cases, while some have proposed the use of ACE Inhibitors (ACEI) or Angiotensin Receptor blockers (ARB), since this virus shares hemagglutinin as a transmission mechanism and acts on the ACE2 enzyme during infection. The aim is to evaluate whether the admitted patients who are previously vaccinated or those who were already receiving treatment show a better evolution.
Description: exitus vs hospital output
Measure: hospital output Time: from March 1, 2020.Description: lenght of the hospital stay
Measure: hospital stay Time: From March 1, 2020.Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, enters type II pneumocytes using angiotensin-converting enzyme 2 (ACE2). It is unclear whether ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) increase, decrease, or have no significant effect on ACE2 expression or activity. Therefore, ACEI and ARB may be harmful, beneficial, or have no impact on Coronavirus Disease 2019 severity and mortality. The Specific Aims of this observational study are: (1) Among SARS-CoV-2-positive outpatients, compare all-cause hospitalization and mortality rates between: 1.1 Current users of a range of doses of ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 1.2 Current users of a range of doses of ACEI- vs. ARB-based regimens, and (2) Among those hospitalized for COVID-19, compare all-cause mortality between: 2.1 Current users of a range of doses of ACEI/ARB- vs. non- ACEI/ARB-based regimens, and 2.2 Current users of a range of doses of ACEI- vs. ARB-based regimens.
Description: For outpatient Veterans with a positive SARS-CoV-2 test (Aims 1.1 and 1.2), the primary outcome is a composite of time to all-cause hospitalization or all-cause mortality.
Measure: All-Cause-Hospitalization or All-Cause Mortality Time: Through study completion (approximately July 31, 2020).Description: For Veterans hospitalized with COVID-19 (Aims 2.1 and 2.2), the primary outcome is time to all-cause mortality.
Measure: All-Cause Mortality Time: Through study completion (approximately July 31, 2020).Description: For aims 1 and 2, a secondary outcome will be time to intensive care unit (ICU) admission.
Measure: ICU admission Time: Through study completion (approximately July 31, 2020).Description: For aims 1 and 2, a secondary outcome will be duration of hospitalization.
Measure: Duration of hospitalization Time: Through study completion (approximately July 31, 2020).Description: For aim 2, a secondary outcome will be time to mechanical ventilation.
Measure: Mechanical ventilation Time: Through study completion (approximately July 31, 2020).Description: For aim 2, a secondary outcome will be time to in-hospital dialysis.
Measure: Dialysis Time: Through study completion (approximately July 31, 2020).Description: Time to gastrointestinal bleed. This will be a negative control outcome.
Measure: Gastrointestinal bleed Time: Through study completion (approximately July 31, 2020).Description: Time to urinary tract infection. This will be a negative control outcome.
Measure: Urinary tract infection Time: Through study completion (approximately July 31, 2020).Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports